Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1NTVQ)

Drug Name

Tadekinig alfa Drug Info

Indication

Disease Entry	ICD 11	Status	REF
XIAP deficiency	4A01.22	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-18 (IL18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK-1070806	DMQGPLO	Type-2 diabetes	5A11	Phase 2	[3]
MEDI-2338	DMCMYPX	Chronic obstructive pulmonary disease	CA22	Phase 1	[4]
Iboctadekin	DMHS29U	Non-hodgkin lymphoma	2B33.5	Phase 1	[5]
IL-18BP	DMRSJ49	B-cell non-hodgkin lymphoma	2B33.5	Discontinued in Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03512314) Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of AB2 Bio.
3	Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220.
4	Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 397-412.
5	Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78.
6	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.